Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

Claudia Trojaniello, Lucia Festino, Vito Vanella, Paolo A. Ascierto

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard of care for patients with advanced BRAF V600 mutation-positive melanoma. With the currently available combinations of dabrafenib plus trametinib and vemurafenib plus cobimetinib, median progression-free survival (PFS) of over 12 months has been achieved. However, treatment resistance and disease recurrence remain a clinical challenge. Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations. Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6 months in the phase III COLUMBUS trial. PFS also appears to be improved with encorafenib plus binimetinib. This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class. Increased specificity of encorafenib may also result in better tolerability with less off-target effects, including reduced occurrence of pyrexia and photosensitivity. Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK inhibitor combinations.

Original languageEnglish
Pages (from-to)259-266
Number of pages8
JournalExpert Review of Clinical Pharmacology
Volume12
Issue number3
DOIs
Publication statusPublished - Mar 4 2019

Fingerprint

Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Disease-Free Survival
Disease Resistance
Survival
Expert Testimony
Standard of Care
MEK162
encorafenib
Fever
Therapeutics
Pharmacokinetics
Recurrence
Pharmaceutical Preparations

Keywords

  • Binimetinib
  • BRAF inhibitor
  • encorafenib
  • MEK inhibitor
  • melanoma
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. / Trojaniello, Claudia; Festino, Lucia; Vanella, Vito; Ascierto, Paolo A.

In: Expert Review of Clinical Pharmacology, Vol. 12, No. 3, 04.03.2019, p. 259-266.

Research output: Contribution to journalReview article

@article{32038ac68d5f4c97841565c69bf59fc1,
title = "Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations",
abstract = "Introduction: Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard of care for patients with advanced BRAF V600 mutation-positive melanoma. With the currently available combinations of dabrafenib plus trametinib and vemurafenib plus cobimetinib, median progression-free survival (PFS) of over 12 months has been achieved. However, treatment resistance and disease recurrence remain a clinical challenge. Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations. Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6 months in the phase III COLUMBUS trial. PFS also appears to be improved with encorafenib plus binimetinib. This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class. Increased specificity of encorafenib may also result in better tolerability with less off-target effects, including reduced occurrence of pyrexia and photosensitivity. Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK inhibitor combinations.",
keywords = "Binimetinib, BRAF inhibitor, encorafenib, MEK inhibitor, melanoma, targeted therapy",
author = "Claudia Trojaniello and Lucia Festino and Vito Vanella and Ascierto, {Paolo A.}",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/17512433.2019.1570847",
language = "English",
volume = "12",
pages = "259--266",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "3",

}

TY - JOUR

T1 - Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

AU - Trojaniello, Claudia

AU - Festino, Lucia

AU - Vanella, Vito

AU - Ascierto, Paolo A.

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Introduction: Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard of care for patients with advanced BRAF V600 mutation-positive melanoma. With the currently available combinations of dabrafenib plus trametinib and vemurafenib plus cobimetinib, median progression-free survival (PFS) of over 12 months has been achieved. However, treatment resistance and disease recurrence remain a clinical challenge. Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations. Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6 months in the phase III COLUMBUS trial. PFS also appears to be improved with encorafenib plus binimetinib. This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class. Increased specificity of encorafenib may also result in better tolerability with less off-target effects, including reduced occurrence of pyrexia and photosensitivity. Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK inhibitor combinations.

AB - Introduction: Combination treatment with a BRAF inhibitor and MEK inhibitor is the standard of care for patients with advanced BRAF V600 mutation-positive melanoma. With the currently available combinations of dabrafenib plus trametinib and vemurafenib plus cobimetinib, median progression-free survival (PFS) of over 12 months has been achieved. However, treatment resistance and disease recurrence remain a clinical challenge. Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations. Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6 months in the phase III COLUMBUS trial. PFS also appears to be improved with encorafenib plus binimetinib. This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class. Increased specificity of encorafenib may also result in better tolerability with less off-target effects, including reduced occurrence of pyrexia and photosensitivity. Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK inhibitor combinations.

KW - Binimetinib

KW - BRAF inhibitor

KW - encorafenib

KW - MEK inhibitor

KW - melanoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85061790374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061790374&partnerID=8YFLogxK

U2 - 10.1080/17512433.2019.1570847

DO - 10.1080/17512433.2019.1570847

M3 - Review article

VL - 12

SP - 259

EP - 266

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -